alexa Comparison of Clinic-Pathological, Molecular Features and PD-L1 Status in a Series of Non-small Cell Lung Cancers: Are Real Life Data Similar to Clinical Trials results?| Abstract
ISSN: 2157-7099

Journal of Cytology & Histology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
  • Research Article   
  • J Cytol Histol 2019, Vol 10(3): 541

Comparison of Clinic-Pathological, Molecular Features and PD-L1 Status in a Series of Non-small Cell Lung Cancers: Are Real Life Data Similar to Clinical Trials results?

Elshiekh M1#, Mani A2#, Kitson R3, Josephides E4, Clifford A4, Rieu R4, Desai S1, Gupta N1, Berry M5, Bloch S5, Ross C5, Anderson J6, Nandi J6, Roddie M7, Copley S7, Denton A8, Hatcher O4, Power D4, Lewanski C4, Newsom-Davis T3 and Patrizia Viola1*
1Department of Cellular Pathology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
2Department of Thoracic Surgery, Royal Brompton and Harefield Hospitals NHS Trust, London, UK
3Department of Oncology, Chelsea and Westminster Hospital, London, UK
4Department of Oncology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
5Department of Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK
6Department of Cardiothoracic Surgery, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
7Department of Radiology, Imperial College Healthcare NHS Trust, London, UK
8Department of Oncology, Mount Vernon Cancer Centre and North West London Hospitals NHS Trust, London, UK
#Contributed equally to this work
*Corresponding Author : Patrizia Viola, MD, Consultant Cellular Pathologist, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Cellular Pathology Building 541, Du Cane Road, London, W120HS, UK, Tel: +447561045812, Email: [email protected]

Received Date: Apr 30, 2019 / Accepted Date: May 24, 2019 / Published Date: May 31, 2019

Abstract

Objective: Immunotherapy is a promising treatment option for a subset of lung cancers as it utilizes the host’s own immune system to attack tumors cells. Selection of patients who are likely to respond to immunotherapy is based on PD-L1 expression, a specific biomarker. Clinic-pathological correlation of PD-L1 status and NSCLC has been explored in several studies and large clinical trials. However, there is discrepancy of data as several antibodies are available. We looked at a series of lung tumors to study the association between PD-L1 expression and patient characteristics in our daily setting to improve the selection of patients more likely to express this marker. Results were compared to those available in literature using the same antibody.
Methods: We analysed PD-L1 status (using Dako clone 22C3) in 170 non-small cell lung cancers and correlated their PD-L1 status with clinical, pathological and molecular characteristics focusing in particular on EGFR and ALK status.
Results: We found a statistically significant association between PD-L1 status, histological pattern in the
adenocarcinomas subtype and stage of the disease.
Conclusion: Our results support the current findings that PD-L1 expression more frequently occurs in advanced stage disease and certain histological pattern. Our data also confirmed longer survival in PD-L1 positive patients.
Highlights
• Immunotherapy is a promising option for the treatment of NSCLC
• PD-L1 status detected by immunohistochemistry is linked to immunotherapy response.
• There are many clones available but only 22C3 is approved as companion diagnostic
• Patient selection can be affected by the antibody used.

Keywords: PD-L1 clone 22C3; Non-small cell lung carcinoma; Immunotherapy; Pembrolizumab

Citation: Elshiekh M, Mani A, Kitson R, Josephides E, Clifford A, et al. (2019) Comparison of Clinic-Pathological, Molecular Features and PD-L1 Status in a Series of Non-small Cell Lung Cancers: Are Real Life Data Similar to Clinical Trials results? J Cytol Histol 10: 541.

Copyright: © 2019 Elshiekh M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 377
  • [From(publication date): 0-0 - Oct 15, 2019]
  • Breakdown by view type
  • HTML page views: 338
  • PDF downloads: 39
Leave Your Message 24x7
Top